Axsome Therapeutics, Inc. (AXSM) Social Stream
AXSOME THERAPEUTICS INC (AXSM) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering AXSM.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-09 | 12 | $180 | $34 | $98.272 | $74.52 | 31.87% |
| 2021-12-17 | 11 | $180 | $34 | $98.272 | $74.52 | 31.87% |
| 2021-12-20 | 11 | $180 | $26 | $95.727 | $74.52 | 28.46% |
| 2022-03-02 | 11 | $180 | $26 | $89.363 | $74.52 | 19.92% |
| 2022-03-07 | 11 | $180 | $31 | $88.454 | $74.52 | 18.7% |
| 2022-03-29 | 11 | $180 | $31 | $89 | $74.52 | 19.43% |
| 2022-04-21 | 11 | $180 | $34 | $90.454 | $74.52 | 21.38% |
| 2022-04-25 | 11 | $180 | $34 | $90.272 | $74.52 | 21.14% |
| 2022-04-27 | 11 | $180 | $27 | $88.181 | $74.52 | 18.33% |
| 2022-05-03 | 11 | $180 | $27 | $87.727 | $74.52 | 17.72% |
| 2022-06-02 | 11 | $180 | $27 | $86.636 | $74.52 | 16.26% |
| 2022-07-11 | 10 | $180 | $28 | $89.4 | $74.52 | 19.97% |
| 2022-08-10 | 10 | $180 | $28 | $89.5 | $74.52 | 20.1% |
| 2022-08-13 | 10 | $180 | $28 | $87.1 | $74.52 | 16.88% |
| 2022-08-21 | 10 | $180 | $34 | $90.6 | $74.52 | 21.58% |
| 2022-08-23 | 10 | $180 | $34 | $101.5 | $74.52 | 36.21% |
| 2022-09-02 | 10 | $210 | $34 | $106.5 | $74.52 | 42.91% |
| 2022-09-17 | 11 | $210 | $34 | $109.2 | $74.52 | 46.54% |
| 2022-10-04 | 11 | $210 | $34 | $108.1 | $74.52 | 45.06% |
| 2022-10-13 | 12 | $210 | $34 | $108.4 | $74.52 | 45.46% |
| 2022-10-24 | 12 | $210 | $35 | $104.272 | $74.52 | 39.92% |
| 2022-11-04 | 13 | $210 | $35 | $103.5 | $74.52 | 38.89% |
| 2022-11-08 | 13 | $210 | $35 | $103.416 | $74.52 | 38.78% |
| 2022-11-09 | 13 | $210 | $35 | $103.75 | $74.52 | 39.22% |
| 2022-11-18 | 13 | $210 | $34 | $105 | $74.52 | 40.9% |
| 2022-11-28 | 13 | $210 | $35 | $105.083 | $74.52 | 41.01% |
| 2022-11-29 | 13 | $210 | $34 | $108.416 | $74.52 | 45.49% |
| 2023-01-03 | 14 | $210 | $52 | $109 | $74.52 | 46.27% |
| 2023-01-26 | 15 | $210 | $52 | $106.571 | $74.52 | 43.01% |
| 2023-01-30 | 15 | $210 | $52 | $107 | $74.52 | 43.59% |
The Trend in the Analyst Price Target
AXSM's average price target has moved down $36.85 over the prior 22 months.
AXSM reports an average of 111.18% for its upside potential over the past 51 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-03-02 | 11 | 180 | 31 | 88.454 | 31.45 | 181.25% |
| 2022-04-27 | 11 | 180 | 27 | 88.181 | 30.50 | 189.12% |
| 2022-10-14 | 12 | 210 | 35 | 104.272 | 48.00 | 117.23% |
| 2023-01-03 | 14 | 210 | 52 | 109.000 | 73.32 | 48.66% |
| 2023-01-24 | 15 | 210 | 52 | 106.571 | 70.81 | 50.5% |
AXSM Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.47 | 12 | 0 | 2 | 0 | 0 | 15 |
The Trend in the Broker Recommendations
Over the past 15 months, AXSM's average broker recommendation rating improved by 0.4.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In the context of all US stocks, AXSOME THERAPEUTICS INC's variance in analysts' estimates is lower than -3381.45% of them.
- AXSOME THERAPEUTICS INC's number of analysts covering the stock is greater than 3095.68% of stocks in the mid market cap category.
- AXSOME THERAPEUTICS INC's average analyst price target is greater than 3058.66% of stocks in the mid market cap category.
- In the context of Pharmaceutical Products stocks, AXSOME THERAPEUTICS INC's upside potential (average analyst target price relative to current price) is higher than 829.37% of them.
In the Pharmaceutical Products industry, BPMC, MCRB, and SIOX are the three stocks most similar to AXSOME THERAPEUTICS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Is AXSM a Buy, Hold or Sell? See the POWR Ratings now!